CERT Certara
Price Chart
Executive Summary
Certara announced that its Simcyp® Simulator was used to support the FDA's acceptance of PBPK modeling in lieu of clinical studies for the approval of asciminib (Scemblix®), a first-in-class treatment for Chronic Myeloid Leukemia. This marks a significant regulatory validation of Certara's model-informed drug development technology, highlighting its ability to replace at least ten clinical pharmacology studies and streamline the NDA process.
Actionable Insight
Traders should view this as a strong validation of Certara's technology platform, likely to enhance commercial credibility and drive adoption across biopharma clients. Monitor for follow-on announcements regarding new client engagements or expanded use of Simcyp in other NDAs.
Key Facts
- FDA accepted PBPK modeling via Certara's Simcyp Simulator in lieu of clinical studies for asciminib (Scemblix®) NDA approval.
- Modeling replaced at least ten dedicated clinical pharmacology studies.
- Asciminib is a first-in-class allosteric inhibitor for Chronic Myeloid Leukemia (CML).
- Simcyp's modeling supported dosing regimens and drug interaction profiles across diverse populations.
- Novartis, a Simcyp Consortium member, led the modeling work in collaboration with Certara.
Financial Impact
Significant long-term revenue potential as regulatory acceptance strengthens demand for Certara’s biosimulation tools; validation could lead to broader adoption and expanded contracts.
Risk Factors
- Revenue impact may be delayed as adoption cycles in biopharma are long.
- Success depends on continued regulatory acceptance beyond this single case.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3248265 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 11, 2026
29d ago
|
8-K
| $5.13 $4.56 | ▲ +11.11% | ▲ +11.03% | $5.18 (−0.97%) |
|
May 11, 2026
29d ago
|
Press Release
| $5.13 $4.56 | ▲ +11.11% | ▲ +11.03% | $5.18 (−0.97%) |
|
Apr 22, 2026
6w ago
|
8-K / PRESS-RELEASE
| $6.38 $6.11 | ▼ −4.23% | ▼ −4.29% | $5.18 (−18.81%) |
|
Apr 3, 2026
9w ago
|
DEFA14A
| $5.46 $5.79 | ▲ +6.04% | ▲ +1.91% | $5.18 (−5.13%) |
|
Mar 30, 2026
10w ago
|
Court Ruling
| $5.68 $5.62 | ▼ −1.06% | ▼ −5.36% | $5.18 (−8.80%) |
|
Mar 3, 2026
14w ago
|
Press Release
| $7.24 $6.93 | ▼ −4.28% | ▼ −3.80% | $5.18 (−28.45%) |
|
Feb 26, 2026
14w ago
|
8-K
| $6.80 $7.15 | ▲ +5.15% | ▲ +6.27% | $5.18 (−23.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access